TG Therapeutics posts Q4 net income $23.3M; FY 2024 BRIUMVI revenue $310M, guides 2025 global rev ~$540M

TG THERAPEUTICS, INC.

Q4 2024 BRIUMVI U.S. net revenue $103.6M; full year $310M, representing ~250% YoY growth.
Net income of $23.3M in Q4 2024 vs net loss of $14.4M in Q4 2023; full year net income $23.4M.
2025 guidance: total global revenue ~$540M, including BRIUMVI U.S. net revenue ~$525M; operating expenses ~$300M.
Cash, cash equivalents and investments $311M as of Dec 31, 2024; company expects sufficient funding from revenues.
Pipeline: Phase 1 trials for subcutaneous ublituximab in MS and MG; licensed azer-cel CAR T for autoimmune indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.